Altimmune Added to Nasdaq Biotechnology Index
19. Dezember 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology...
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
02. Dezember 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
Altimmune to Participate at Two Upcoming Investor Conferences
26. November 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
15. November 2024 11:00 ET
|
Altimmune, Inc
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on...
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
12. November 2024 07:00 ET
|
Altimmune, Inc
Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11. November 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
11. November 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial...
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
07. November 2024 07:30 ET
|
Altimmune, Inc
Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and...
Altimmune to Participate at Two Upcoming Investor Conferences
06. November 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
04. November 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial...